Zevra Therapeutics, Inc. (ZVRA) Stock Analysis

Company Overview

Zevra Therapeutics, Inc. operates as a commercial-stage biotechnology entity dedicated to addressing unmet medical needs for the treatment of rare diseases within the United States market. The company leverages its proprietary Ligand Activated Technology platform to develop product candidates, with KP1077 serving as its lead initiative, which consists of the compound KP1077IH. This biotechnology firm functions within the broader healthcare sector, where its specific focus on rare disease therapeutics distinguishes its operational landscape from standard pharmaceutical development models. The company currently maintains a market capitalization of $537.21M, supports an annual revenue stream of $106.47M, and employs a workforce of 61 individuals. These valuation and revenue figures indicate a mid-sized market capitalization that suggests the company has achieved significant commercial traction while maintaining a lean organizational structure typical of specialized biotechnology firms.

Financial Health

Zevra Therapeutics reported a trailing twelve-month revenue of $106.47M and a net income of $77.58M, while recording an EBITDA of -$179,000. The substantial gap between the high net income figure and the negligible negative EBITDA reveals a unique cost structure where non-operating income or specific accounting adjustments significantly impact the bottom line relative to core operating cash flows. The company generated free cash flow of -$1,955,250, which indicates that despite profitable net income, the business is currently burning cash on a run-rate basis, reflecting the capital-intensive nature of its development and commercialization activities. The company maintains a cash balance of $191.01M against total debt of $63.21M, resulting in a debt-to-equity ratio of 40.87. This balance sheet composition, coupled with the high cash reserves, suggests a conservative liquidity position where cash assets significantly exceed debt obligations. The current ratio stands at 5.68, a figure that indicates robust short-term liquidity and an ability to meet its current liabilities with ease using its current assets. Return on Equity is reported at 85.7%, while Return on Assets is -1.1%, metrics that collectively reveal high leverage amplifying shareholder returns but also highlighting challenges in generating asset-level profitability relative to the total asset base.

Valuation Assessment

The trailing twelve-month P/E ratio is 6.78, while the forward P/E ratio is 6.02, implying that the market expects earnings growth that will compress the valuation multiple over the coming year. The price-to-book ratio is 3.36, which indicates that the market is pricing the company at a significant premium over its book value, suggesting high expectations for future growth or asset appreciation. Alternative valuation metrics include a price-to-sales ratio of 5.05 and an EV/EBITDA of -2313.42, figures that suggest the market is valuing the company primarily on revenue and equity rather than current earnings power or enterprise value multiples. The stock has a 52-week high of $13.16 and a 52-week low of $6.19, providing a trading range within which the current price fluctuates based on market sentiment and sector rotation. The beta value is 0.94, which means the stock's price volatility closely mirrors that of the broader market, exhibiting slightly less sensitivity to market swings than a stock with a beta of 1.0.

Growth & Income

Revenue growth year-over-year is recorded at 183.4%, while earnings growth is listed as N/A, indicating that the rapid expansion in revenue has not yet translated into a standard year-over-year earnings growth rate in the traditional sense. The company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning the company reinvests all available earnings into research, development, and commercial expansion rather than distributing income to shareholders. The absence of a dividend payout confirms the company's strategy of retaining capital to fuel its commercial-stage operations and platform development. Overall, the company presents a high-growth revenue profile supported by a conservative balance sheet, with no current income generation through dividends, focusing entirely on expanding its market presence in the rare disease therapeutic space.